Moberg Pharma AB (publ) (MOB.ST)
SEK 7.95
(2.65%)
SEK 7.95
(2.65%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 3.46 Million SEK | -13.06% |
| 2022 | 3.98 Million SEK | 222.91% |
| 2021 | 1.23 Million SEK | -74.02% |
| 2020 | 4.75 Million SEK | 0.0% |
| 2018 | 594.51 Million SEK | 0.46% |
| 2017 | 591.78 Million SEK | 0.47% |
| 2016 | 589.04 Million SEK | 0.0% |
| 2015 | - SEK | -100.0% |
| 2014 | 3.33 Million SEK | -80.0% |
| 2013 | 16.66 Million SEK | -40.0% |
| 2012 | 27.77 Million SEK | 0.0% |
| 2011 | - SEK | -100.0% |
| 2010 | 150 Thousand SEK | -50.41% |
| 2009 | 302.5 Thousand SEK | -55.35% |
| 2008 | 677.5 Thousand SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 3.13 Million SEK | 0.0% |
| 2024 Q2 | 2.7 Million SEK | 0.0% |
| 2023 Q2 | 2.79 Million SEK | -10.48% |
| 2023 Q3 | 2.81 Million SEK | 0.89% |
| 2023 Q4 | 3.46 Million SEK | 22.99% |
| 2023 FY | 3.46 Million SEK | -13.06% |
| 2023 Q1 | 3.12 Million SEK | -21.74% |
| 2022 Q3 | - SEK | -100.0% |
| 2022 FY | 3.98 Million SEK | 222.91% |
| 2022 Q4 | 3.98 Million SEK | 0.0% |
| 2022 Q1 | 544 Thousand SEK | -55.95% |
| 2022 Q2 | 689 Thousand SEK | 26.65% |
| 2021 Q2 | 3.41 Million SEK | -16.45% |
| 2021 Q4 | 1.23 Million SEK | -54.86% |
| 2021 FY | 1.23 Million SEK | -74.02% |
| 2021 Q1 | 4.08 Million SEK | -14.08% |
| 2021 Q3 | 2.73 Million SEK | -19.81% |
| 2020 Q3 | 5.19 Million SEK | 0.0% |
| 2020 Q1 | 6.45 Million SEK | -8.87% |
| 2020 FY | 4.75 Million SEK | 0.0% |
| 2020 Q4 | 4.75 Million SEK | -8.42% |
| 2019 Q4 | 7.08 Million SEK | -8.88% |
| 2019 Q1 | 32.21 Million SEK | -94.58% |
| 2019 Q2 | 32.03 Million SEK | -0.56% |
| 2019 Q3 | 7.77 Million SEK | -75.74% |
| 2018 Q2 | 593.12 Million SEK | 0.11% |
| 2018 FY | 594.51 Million SEK | 0.46% |
| 2018 Q4 | 594.51 Million SEK | 0.12% |
| 2018 Q3 | 593.78 Million SEK | 0.11% |
| 2018 Q1 | 592.45 Million SEK | 0.11% |
| 2017 Q2 | 590.45 Million SEK | 0.11% |
| 2017 Q1 | 589.79 Million SEK | 0.13% |
| 2017 FY | 591.78 Million SEK | 0.47% |
| 2017 Q4 | 591.78 Million SEK | 0.11% |
| 2017 Q3 | 591.12 Million SEK | 0.11% |
| 2016 Q2 | 293.98 Million SEK | 0.11% |
| 2016 Q3 | 397.37 Million SEK | 35.17% |
| 2016 Q4 | 589.04 Million SEK | 48.23% |
| 2016 FY | 589.04 Million SEK | 0.0% |
| 2016 Q1 | 293.65 Million SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 FY | - SEK | -100.0% |
| 2015 Q1 | - SEK | -100.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2014 Q4 | 3.33 Million SEK | -61.9% |
| 2014 Q3 | 8.74 Million SEK | -26.61% |
| 2014 Q1 | 15.2 Million SEK | -8.78% |
| 2014 Q2 | 11.92 Million SEK | -21.6% |
| 2014 FY | 3.33 Million SEK | -80.0% |
| 2013 Q1 | 39.27 Million SEK | 41.4% |
| 2013 Q3 | 21.46 Million SEK | -46.36% |
| 2013 FY | 16.66 Million SEK | -40.0% |
| 2013 Q4 | 16.66 Million SEK | -22.36% |
| 2013 Q2 | 40.02 Million SEK | 1.89% |
| 2012 Q4 | 27.77 Million SEK | 0.0% |
| 2012 FY | 27.77 Million SEK | 0.0% |
| 2012 Q3 | - SEK | 0.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 Q1 | - SEK | 0.0% |
| 2011 FY | - SEK | -100.0% |
| 2011 Q2 | 75 Thousand SEK | -33.33% |
| 2011 Q4 | - SEK | -100.0% |
| 2011 Q3 | 37.5 Thousand SEK | -50.0% |
| 2011 Q1 | 112.5 Thousand SEK | -25.0% |
| 2010 FY | 150 Thousand SEK | -50.41% |
| 2010 Q4 | 150 Thousand SEK | 0.0% |
| 2009 FY | 302.5 Thousand SEK | -55.35% |
| 2008 FY | 677.5 Thousand SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 26.35 Million SEK | 86.846% |
| Enzymatica AB (publ) | 24.88 Million SEK | 86.067% |
| Enorama Pharma AB (publ) | 303 Thousand SEK | -1044.224% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
| Nanexa AB (publ) | 2.08 Million SEK | -66.124% |
| Newbury Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| ODI Pharma AB | - SEK | -Infinity% |
| Orexo AB (publ) | 448.4 Million SEK | 99.227% |
| Probi AB (publ) | 38.21 Million SEK | 90.927% |
| Swedencare AB (publ) | 1.44 Billion SEK | 99.759% |
| Swedish Orphan Biovitrum AB (publ) | 11.35 Billion SEK | 99.969% |
| Toleranzia AB | 850 Thousand SEK | -307.882% |
| Vivesto AB | 5.18 Million SEK | 33.082% |